These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25492617)

  • 21. Competing designs for phase I clinical trials: a review.
    Rosenberger WF; Haines LM
    Stat Med; 2002 Sep; 21(18):2757-70. PubMed ID: 12228889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A statistical evaluation of dose expansion cohorts in phase I clinical trials.
    Boonstra PS; Shen J; Taylor JM; Braun TM; Griffith KA; Daignault S; Kalemkerian GP; Lawrence TS; Schipper MJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
    Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
    Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A two-dimensional biased coin design for dual-agent dose-finding trials.
    Sun Z; Braun TM
    Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
    Lee SM; Wages NA; Goodman KA; Lockhart AC
    JCO Precis Oncol; 2021 Jan; 5():317-324. PubMed ID: 34151131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An approach to meta-analysis of dose-finding studies.
    Zohar S; Katsahian S; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continual reassessment and related designs in dose-finding studies.
    Iasonos A; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2057-61. PubMed ID: 21351292
    [No Abstract]   [Full Text] [Related]  

  • 31. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.
    Mandrekar SJ
    Am Soc Clin Oncol Educ Book; 2014; ():e107-10. PubMed ID: 24857087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
    Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
    Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental designs for phase I and phase I/II dose-finding studies.
    O'Quigley J; Zohar S
    Br J Cancer; 2006 Mar; 94(5):609-13. PubMed ID: 16434987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.